Fundraising Fox
TwoStep Therapeutics
San Carlos, US · Founded 2023 · Delaware corporation · 12 employees on LinkedIn · 4 known investors
Find your way into TwoStep Therapeutics
Sign up to see every warm intro you have to TwoStep Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the TwoStep Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
TwoStep Therapeutics is a Stanford spinout developing targeted cancer therapies, including peptide-based drug conjugates and radioligand programs built on a tumor-targeting peptide platform. The company is advancing a preclinical pipeline toward a first clinical trial planned for the second half of 2026.
Founders & leadership
TwoStep Therapeutics was founded in 2023 by Caitlyn Miller, Jennifer Cochran, Carolyn Bertozzi, and Ronald Levy.
CM
Caitlyn MillerCo-Founder & CEOCaitlyn Miller holds a PhD in Bioengineering from Stanford University, where she worked in the labs of Carolyn Bertozzi and Jennifer Cochran; she served as Entrepreneur-In-Residence at the Stanford Innovative Medicines Accelerator before co-founding TwoStep Therapeutics.
JC
Jennifer CochranCo-Founder
CB
Carolyn BertozziCo-Founder
RL
Ronald LevyCo-Founder
Board
OA
JP
John PrufetaBoard directorChief Executive Officer and Managing Partner at Medical Excellence Capital
MP
Matias Porras PaniaguaBoard director
Investors · 4
2048 Ventureslisted by 2048 VenturesNew York · $500K – $3M
How we know: 2048 Ventures's portfolio page · the VCSheet dataset · Not right? Tell us
Fifty Yearslisted by Fifty YearsSan Francisco · $250K – $2M
How we know: Fifty Years's portfolio page · Not right? Tell us
Medical Excellence Capitallisted by Medical Excellence CapitalNew York
How we know: Medical Excellence Capital's portfolio page · Not right? Tell us
NFXlisted by NFXSan Francisco · $250K – $5Mvia Omri Drory · board
How we know: a partner's Signal profile · board seat on SEC Form D · funding news · press coverage · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$27.6M disclosed across 2 rounds · 2024–2026
▶$21.1MraisedJan 2026 · 8 investors · OtherRule 506(b)
▶$21.1MraisedJan 2026 · 8 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Matias Porras PaniaguaDirector
- Caitlyn MillerExecutive Officer, Director, Promoter
- Omri Amirav-DroryDirector
- John PrufetaDirector
- Offering amount
- $62.2M
- Amount sold
- $21.1M
- First sale
- Jan 2026
- Incorporated
- Corporation, Delaware, 2023
- Federal exemptions
- 06b
▶$6.5MraisedMar 2024 · 6 investors · OtherRule 506(b)
▶$6.5MraisedMar 2024 · 6 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Caitlyn MillerExecutive Officer, Director, Promoter
- Omri Amirav-DroryDirector
- Offering amount
- $6.5M
- Amount sold
- $6.5M
- First sale
- Mar 2024
- Incorporated
- Corporation, Delaware, 2023
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 8
SoluSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Transcode TherapeuticsTransCode Therapeutics is an RNA-focused drug developer building oncology therapeutic candidates and diagnostics, using its TTX delivery technology across immunotherapy, gene editing, radiotherapy, and cancer vaccines. Its pipeline targets cancers such as pancreatic cancer through RNAi, RIG-I agonism, CRISPR, radioisotope delivery, and mRNA-based vaccines.
Stoke TherapeuticsStoke Therapeutics develops RNA-based antisense oligonucleotides to treat severe genetic diseases by restoring protein expression through its TANGO platform, with a lead program in late-stage clinical development for Dravet syndrome and additional programs targeting other genetic disorders of the central nervous system and eye.
A2 BiotherapeuticsA2 Bio develops precision CAR T-cell therapies using its Tmod cell engineering platform, supporting both autologous and allogeneic applications. The company targets cancer and other serious diseases, advancing its cell therapies through clinical trials.
Nested TherapeuticsNested Therapeutics is a precision oncology company developing small-molecule cancer therapeutics by identifying overlooked driver mutations and novel binding pockets through a drug discovery platform combining genomics, computational biophysics, machine learning, and chemical biology. Its lead program, NST-628, is a brain-penetrant pan-RAF/MEK molecular glue in Phase 1 trials for MAPK-driven solid tumors, alongside a mutation-selective p53-pathway program.
Applied TherapeuticsApplied Therapeutics is a biopharmaceutical company developing novel drugs for rare diseases with high unmet medical need. Its Aldose Reductase Inhibitor franchise is in development across disease areas including Galactosemia and SORD Deficiency.
BiotechtvBiotechTV is a media outlet producing video shows, event coverage, and news focused on the biotech and healthcare sectors, including topics like venture funding, oncology conferences, and drug development. Its programming covers industry events, CEO interviews, science spotlights, and AI news for a biotech and life sciences audience.
Companies working in the same space as TwoStep Therapeutics.
Frequently asked questions
- What does TwoStep Therapeutics do?
- TwoStep Therapeutics is a Stanford spinout developing targeted cancer therapies, including peptide-based drug conjugates and radioligand programs built on a tumor-targeting peptide platform. The company is advancing a preclinical pipeline toward a first clinical trial planned for the second half of 2026.
- Who founded TwoStep Therapeutics?
- TwoStep Therapeutics was founded by Caitlyn Miller, Jennifer Cochran, Carolyn Bertozzi, Ronald Levy in 2023.
- Who are TwoStep Therapeutics's investors?
- TwoStep Therapeutics's investors include 2048 Ventures, Fifty Years, Medical Excellence Capital, NFX.
- How much funding has TwoStep Therapeutics raised?
- TwoStep Therapeutics has disclosed $27.6M raised across 2 rounds.
- Where is TwoStep Therapeutics headquartered?
- TwoStep Therapeutics is headquartered in San Carlos, US.